Cargando…

In Vitro and In Vivo Evaluation of a (18)F-Labeled High Affinity NOTA Conjugated Bombesin Antagonist as a PET Ligand for GRPR-Targeted Tumor Imaging

Expression of the gastrin-releasing peptide receptor (GRPR) in prostate cancer suggests that this receptor can be used as a potential molecular target to visualize and treat these tumors. We have previously investigated an antagonist analog of bombesin (D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH(2), R...

Descripción completa

Detalles Bibliográficos
Autores principales: Varasteh, Zohreh, Åberg, Ola, Velikyan, Irina, Lindeberg, Gunnar, Sörensen, Jens, Larhed, Mats, Antoni, Gunnar, Sandström, Mattias, Tolmachev, Vladimir, Orlova, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3849266/
https://www.ncbi.nlm.nih.gov/pubmed/24312607
http://dx.doi.org/10.1371/journal.pone.0081932
_version_ 1782293898951917568
author Varasteh, Zohreh
Åberg, Ola
Velikyan, Irina
Lindeberg, Gunnar
Sörensen, Jens
Larhed, Mats
Antoni, Gunnar
Sandström, Mattias
Tolmachev, Vladimir
Orlova, Anna
author_facet Varasteh, Zohreh
Åberg, Ola
Velikyan, Irina
Lindeberg, Gunnar
Sörensen, Jens
Larhed, Mats
Antoni, Gunnar
Sandström, Mattias
Tolmachev, Vladimir
Orlova, Anna
author_sort Varasteh, Zohreh
collection PubMed
description Expression of the gastrin-releasing peptide receptor (GRPR) in prostate cancer suggests that this receptor can be used as a potential molecular target to visualize and treat these tumors. We have previously investigated an antagonist analog of bombesin (D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH(2), RM26) conjugated to 1,4,7-triazacyclononane-N,N',N''-triacetic acid (NOTA) via a diethylene glycol (PEG(2)) spacer (NOTA-P2-RM26) labeled with (68)Ga and (111)In. We found that this conjugate has favorable properties for in vivo imaging of GRPR-expression. The focus of this study was to develop a (18)F-labelled PET agent to visualize GRPR. NOTA-P2-RM26 was labeled with (18)F using aluminum-fluoride chelation. Stability, in vitro binding specificity and cellular processing tests were performed. The inhibition efficiency (IC(50)) of the [(nat)F]AlF-NOTA-P2-RM26 was compared to that of the (nat)Ga-loaded peptide using (125)I-Tyr(4)-BBN as the displacement radioligand. The pharmacokinetics and in vivo binding specificity of the compound were studied. NOTA-P2-RM26 was labeled with (18)F within 1 h (60-65% decay corrected radiochemical yield, 55 GBq/µmol). The radiopeptide was stable in murine serum and showed high specific binding to PC-3 cells. [(nat)F]AlF-NOTA-P2-RM26 showed a low nanomolar inhibition efficiency (IC(50)=4.4±0.8 nM). The internalization rate of the tracer was low. Less than 14% of the cell-bound radioactivity was internalized after 4 h. The biodistribution of [(18)F]AlF-NOTA-P2-RM26 demonstrated rapid blood clearance, low liver uptake and low kidney retention. The tumor uptake at 3 h p.i. was 5.5±0.7 %ID/g, and the tumor-to-blood, -muscle and -bone ratios were 87±42, 159±47, 38±16, respectively. The uptake in tumors, pancreas and other GRPR-expressing organs was significantly reduced when excess amount of non-labeled peptide was co-injected. The low uptake in bone suggests a high in vivo stability of the Al-F bond. High contrast PET image was obtained 3 h p.i. The initial biological results suggest that [(18)F]AlF-NOTA-P2-RM26 is a promising candidate for PET imaging of GRPR in vivo.
format Online
Article
Text
id pubmed-3849266
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-38492662013-12-05 In Vitro and In Vivo Evaluation of a (18)F-Labeled High Affinity NOTA Conjugated Bombesin Antagonist as a PET Ligand for GRPR-Targeted Tumor Imaging Varasteh, Zohreh Åberg, Ola Velikyan, Irina Lindeberg, Gunnar Sörensen, Jens Larhed, Mats Antoni, Gunnar Sandström, Mattias Tolmachev, Vladimir Orlova, Anna PLoS One Research Article Expression of the gastrin-releasing peptide receptor (GRPR) in prostate cancer suggests that this receptor can be used as a potential molecular target to visualize and treat these tumors. We have previously investigated an antagonist analog of bombesin (D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH(2), RM26) conjugated to 1,4,7-triazacyclononane-N,N',N''-triacetic acid (NOTA) via a diethylene glycol (PEG(2)) spacer (NOTA-P2-RM26) labeled with (68)Ga and (111)In. We found that this conjugate has favorable properties for in vivo imaging of GRPR-expression. The focus of this study was to develop a (18)F-labelled PET agent to visualize GRPR. NOTA-P2-RM26 was labeled with (18)F using aluminum-fluoride chelation. Stability, in vitro binding specificity and cellular processing tests were performed. The inhibition efficiency (IC(50)) of the [(nat)F]AlF-NOTA-P2-RM26 was compared to that of the (nat)Ga-loaded peptide using (125)I-Tyr(4)-BBN as the displacement radioligand. The pharmacokinetics and in vivo binding specificity of the compound were studied. NOTA-P2-RM26 was labeled with (18)F within 1 h (60-65% decay corrected radiochemical yield, 55 GBq/µmol). The radiopeptide was stable in murine serum and showed high specific binding to PC-3 cells. [(nat)F]AlF-NOTA-P2-RM26 showed a low nanomolar inhibition efficiency (IC(50)=4.4±0.8 nM). The internalization rate of the tracer was low. Less than 14% of the cell-bound radioactivity was internalized after 4 h. The biodistribution of [(18)F]AlF-NOTA-P2-RM26 demonstrated rapid blood clearance, low liver uptake and low kidney retention. The tumor uptake at 3 h p.i. was 5.5±0.7 %ID/g, and the tumor-to-blood, -muscle and -bone ratios were 87±42, 159±47, 38±16, respectively. The uptake in tumors, pancreas and other GRPR-expressing organs was significantly reduced when excess amount of non-labeled peptide was co-injected. The low uptake in bone suggests a high in vivo stability of the Al-F bond. High contrast PET image was obtained 3 h p.i. The initial biological results suggest that [(18)F]AlF-NOTA-P2-RM26 is a promising candidate for PET imaging of GRPR in vivo. Public Library of Science 2013-12-03 /pmc/articles/PMC3849266/ /pubmed/24312607 http://dx.doi.org/10.1371/journal.pone.0081932 Text en © 2013 Varasteh et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Varasteh, Zohreh
Åberg, Ola
Velikyan, Irina
Lindeberg, Gunnar
Sörensen, Jens
Larhed, Mats
Antoni, Gunnar
Sandström, Mattias
Tolmachev, Vladimir
Orlova, Anna
In Vitro and In Vivo Evaluation of a (18)F-Labeled High Affinity NOTA Conjugated Bombesin Antagonist as a PET Ligand for GRPR-Targeted Tumor Imaging
title In Vitro and In Vivo Evaluation of a (18)F-Labeled High Affinity NOTA Conjugated Bombesin Antagonist as a PET Ligand for GRPR-Targeted Tumor Imaging
title_full In Vitro and In Vivo Evaluation of a (18)F-Labeled High Affinity NOTA Conjugated Bombesin Antagonist as a PET Ligand for GRPR-Targeted Tumor Imaging
title_fullStr In Vitro and In Vivo Evaluation of a (18)F-Labeled High Affinity NOTA Conjugated Bombesin Antagonist as a PET Ligand for GRPR-Targeted Tumor Imaging
title_full_unstemmed In Vitro and In Vivo Evaluation of a (18)F-Labeled High Affinity NOTA Conjugated Bombesin Antagonist as a PET Ligand for GRPR-Targeted Tumor Imaging
title_short In Vitro and In Vivo Evaluation of a (18)F-Labeled High Affinity NOTA Conjugated Bombesin Antagonist as a PET Ligand for GRPR-Targeted Tumor Imaging
title_sort in vitro and in vivo evaluation of a (18)f-labeled high affinity nota conjugated bombesin antagonist as a pet ligand for grpr-targeted tumor imaging
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3849266/
https://www.ncbi.nlm.nih.gov/pubmed/24312607
http://dx.doi.org/10.1371/journal.pone.0081932
work_keys_str_mv AT varastehzohreh invitroandinvivoevaluationofa18flabeledhighaffinitynotaconjugatedbombesinantagonistasapetligandforgrprtargetedtumorimaging
AT abergola invitroandinvivoevaluationofa18flabeledhighaffinitynotaconjugatedbombesinantagonistasapetligandforgrprtargetedtumorimaging
AT velikyanirina invitroandinvivoevaluationofa18flabeledhighaffinitynotaconjugatedbombesinantagonistasapetligandforgrprtargetedtumorimaging
AT lindeberggunnar invitroandinvivoevaluationofa18flabeledhighaffinitynotaconjugatedbombesinantagonistasapetligandforgrprtargetedtumorimaging
AT sorensenjens invitroandinvivoevaluationofa18flabeledhighaffinitynotaconjugatedbombesinantagonistasapetligandforgrprtargetedtumorimaging
AT larhedmats invitroandinvivoevaluationofa18flabeledhighaffinitynotaconjugatedbombesinantagonistasapetligandforgrprtargetedtumorimaging
AT antonigunnar invitroandinvivoevaluationofa18flabeledhighaffinitynotaconjugatedbombesinantagonistasapetligandforgrprtargetedtumorimaging
AT sandstrommattias invitroandinvivoevaluationofa18flabeledhighaffinitynotaconjugatedbombesinantagonistasapetligandforgrprtargetedtumorimaging
AT tolmachevvladimir invitroandinvivoevaluationofa18flabeledhighaffinitynotaconjugatedbombesinantagonistasapetligandforgrprtargetedtumorimaging
AT orlovaanna invitroandinvivoevaluationofa18flabeledhighaffinitynotaconjugatedbombesinantagonistasapetligandforgrprtargetedtumorimaging